Vasily Andrianov

Dr. Andrianov joined Inhibrx in January 2021, bringing over 16 years of industry experience in hematology and oncology clinical development.

Before joining Inhibrx, Dr. Andrianov served as a physician-scientist and medical monitor for multiple early-phase studies of various small molecules and Immuno-oncology agents, vaccines, and T-cell therapies for solid tumors, such as melanoma, head and neck, renal cell and prostate cancer, and B-cell lymphomas. He also supported several registrational trials and New Drug Applications in non-small-cell lung cancer, myelodysplastic syndrome, and acute myeloid leukemia, as well as Biologics License Applications in Hemophilia and diffuse large B cells lymphoma.

Dr. Andrianov received an M.D. from the Pavlov First State Medical University of Saint Petersburg and a clinical development professional certification from King’s College London.